Critical Contrast: Smith Micro Software (NASDAQ:SMSI) versus Coeptis Therapeutics (NASDAQ:ZSQR)

Coeptis Therapeutics (NASDAQ:ZSQR) and Smith Micro Software (NASDAQ:SMSI) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Coeptis Therapeutics and Smith Micro Software, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1	0	0	0	1.00
Smith Micro Software	1	0	2	0	2.33

Smith Micro Software has a consensus price target of $12.50, suggesting a potential upside of 436.48%. Given Smith Micro Software’s stronger consensus rating and higher probable upside, analysts clearly believe Smith Micro Software is more favorable than Coeptis Therapeutics.

Earnings and Valuation

This table compares Coeptis Therapeutics and Smith Micro Software”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36 million	152.38	-$11.92 million	($1.63)	-2.40
Smith Micro Software	$17.36 million	0.75	-$29.33 million	($3.52)	-0.66

Coeptis Therapeutics has higher earnings, but lower revenue than Smith Micro Software. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Smith Micro Software, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Coeptis Therapeutics and Smith Micro Software’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Smith Micro Software	-92.60%	-44.59%	-31.78%

Volatility and Risk

Coeptis Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500. Comparatively, Smith Micro Software has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Insider & Institutional Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 20.8% of Smith Micro Software shares are held by institutional investors. 24.2% of Coeptis Therapeutics shares are held by insiders. Comparatively, 34.7% of Smith Micro Software shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Smith Micro Software beats Coeptis Therapeutics on 11 of the 14 factors compared between the two stocks.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

About Smith Micro Software

Smith Micro Software, Inc. engages in the development and sale of software to enhance the mobile experience to wireless and cable service providers in the Americas, Europe, the Middle East, and Africa. The company offers SafePath Family, SafePath IoT, SafePath Home, and SafePath Premium product suite, which provides tools to protect digital lifestyles and manage connected devices inside and outside the home; and CommSuite, a messaging platform that helps mobile service provides deliver a next-generation voicemail experience to mobile subscribers, as well as enables multi-language voice-to-text (VTT) transcription messaging. It also offers ViewSpot, a retail display management platform that provides on-screen and interactive demos to wireless carriers and other smartphone retailers; and technical support and customer services. Smith Micro Software, Inc. was founded in 1982 and is headquartered in Pittsburgh, Pennsylvania.